CYTR

LadRx Corporation Announces OTCQB Ticker Change to LADX

Retrieved on: 
水曜日, 10月 5, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Niemann–Pick disease, Therapy, SEC, CUSIP, ImmunityBio, Patient, Research, Annual report, NPC, Cancer, Gaucher's disease, CYTR, Doctor of Philosophy, Nature, Gaucher, OTCQB, Pharmaceutical industry, Aldoxorubicin

LadRx Corporation (OTCQB: LADX) (LadRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022.

Key Points: 
  • LadRx Corporation (OTCQB: LADX) (LadRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022.
  • Chief Executive Officer Stephen Snowdy, PhD commented, Following up on other changes we have made this year, including the change of our name to LadRx Corporation, we are updating our ticker symbol to better reflect our Companys focus and brand.
  • There is no action required by the Companys current shareholders and the change in its ticker symbol will have no effect on its corporate structure or business.
  • LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer.